ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.
Q4 2025 Earnings Call February 24, 2026 4:30 PM ESTCompany ParticipantsBill Roeschlein - Chief Financial OfficerZvi Alon - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results